Navigation Links
New Licence for Cubicin(R) (daptomycin), the First in a Novel Class of Antibiotic, is Announced Today for the Treatment of Serious Bloodstream and Heart Infections Caused by the Most Problematic UK Organisms, Including MRSA
Date:9/12/2007

FRIMLEY, England, September 13 /PRNewswire-FirstCall/ --

- Physicians Welcome New Option for Potentially Life Threatening Disease

- Daptomycin has a Rapidly Bactericidal Mode of Action

The launch of daptomycin for the treatment of both methicillin-sensitive and resistant Staphylococcus aureus (MSSA and MRSA) bloodstream infections (bacteraemia) and heart infections (right-sided infective endocarditis) has been announced today by Novartis Pharmaceuticals UK Ltd.(1) Daptomycin, one of only two new classes of antibiotic in over 20 years, has been shown to be as effective as existing agents in treating a range of serious Gram-positive infections, offering an important new option for healthcare professionals.

MRSA is a frequent cause of bacteraemia and is associated with serious complications, including endocarditis (in 30-40% of cases) and has a high mortality rate.(2) Over 7,000 people each year contract bacteraemia and the incidence is rising.(3) From 1993 to 2005 the number of deaths increased from 51 to 1,629.(4) There is evidence that some strains of MRSA are developing resistance to existing antibiotic options.(5) Daptomycin, which is rapidly bactericidal, has a specific mode of action, which reduces the likelihood of resistance developing. Daptomycin's once daily dosing and tolerability profile, with no need for therapeutic drug monitoring, has the potential to simplify the management of patients with complicated infections.

Dr Andrew Seaton, consultant in infectious diseases, Gartnavel general hospital, Glasgow welcomed the news, commenting; "Serious staphylococcal infections are extremely challenging for hospital specialists to treat, with about 40% in the UK now resistant to first line therapy. Daptomycin is a fast acting agent in these potentially difficult situations and is well tolerated by patients. This is an extremely important and welcomed development in the battle against serious MRSA infection."

Daptomycin is
'/>"/>

SOURCE Novartis Pharmaceuticals UK Ltd
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. The Genesis of Gendicine: The Story Behind the First Gene Therapy
2. Midwest life science stocks sizzle in a tepid first quarter
3. Morgridge Institute for Research seeks first CEO
4. Sonic Foundry reports first cash-positive quarter
5. Angel investors commit $12.7B in first half of `06
6. Aurora team implants Wisconsins first total artificial heart
7. First half of 2006 roundup: Big Pharma trumps biotech
8. GE announces first installation of Discovery VCT
9. GE Healthcare enjoys robust growth in first quarter
10. Madison asks for wireless bids; airport, downtown would be first
11. Tech Digest: Inacom, PKWare at Infosecurity, Firstlogic, Teklynx
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... Southlake, Texas (PRWEB) March 05, 2015 ... treatment of acute and chronic orthopedic conditions such ... runner’s knee, tennis elbow, and joint pain due ... also be administered during orthopedic surgeries to promote ... patented scientific advances in nearly pain-free bone marrow ...
(Date:3/4/2015)... , March 4, 2015 The UPMC ... its 2015 Fellows in the Emerging Leaders in Biosecurity ... future leaders in the field of biosecurity, UPMC has ... from a wide array of backgrounds, including biological science, ... sector. "With the vision and support ...
(Date:3/4/2015)... 04, 2015 Research and Markets ... Jain PharmaBiotech,s new report "Biomarkers - Technologies, ... This report follows the broad definition ... be objectively measured and evaluated as an indicator ... as pharmacological responses to a therapeutic intervention. Tests ...
(Date:3/4/2015)... PRC Clinical, a full-service, ... Bay Area, will exhibit and present at the ... on March 25th and 26th in Tel Aviv, Israel. ... Israeli life science companies seeking to conduct U.S. Food ... span all phases of human trials, from Phase I ...
Breaking Biology Technology:Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 2Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 3Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 4Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 5UPMC Center for Health Security Announces 2015 Emerging Leaders in Biosecurity 2UPMC Center for Health Security Announces 2015 Emerging Leaders in Biosecurity 3Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 2Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 3PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 2PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 3PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 4
...  Bunker Hill Community College (BHCC) celebrated the graduation ... Program (CBCP) in a ceremony that also marked ... a collaborative effort between BHCC,s Workforce Development Center, ... It targets low-income Cambridge residents who complete – ...
... 2012 Rhythm announced today the results of a ... ghrelin agonist for the treatment of diabetic gastroparesis. The ... patients with diabetic gastroparesis. The findings were presented at ... The Phase 1b clinical trial was a ...
... 22, 2012   IntelliCell BioSciences, Inc. ("Company") (OTCQB: SVFC.PK)  announced ... agreement with the Institute for Cell Engineering and ... A portion of the collaborative work will be ... autologous vascular cells that are also referred to ...
Cached Biology Technology:Bunker Hill Community College Holds Biomedical Careers Graduation Ceremony 2Rhythm Announces Phase 1b Results for Ghrelin Prokinetic RM-131 for Diabetic Gastroparesis 2IntelliCell BioSciences Announces Collaborative Agreement with the University of Florida on Stem Cell and Tissue Repair Research 2IntelliCell BioSciences Announces Collaborative Agreement with the University of Florida on Stem Cell and Tissue Repair Research 3
(Date:2/19/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/kx9zp8/military ) ... Electro-Optical / Infrared Systems Market by Type, by ... to 2020" report to their offering. ... expected to reach $16.35 billion by 2020, to ... report segments the military electro-optical/infrared systems market on ...
(Date:2/13/2015)... ACT Genomics Co., Ltd., a cancer ... cancer genomic information into precision diagnosis and personalized ... US$ 8 million in the its first private funding ... Taiwan , ACT Genomics has developed comprehensive ... to implement next generation sequencing (NGS) and multiplex ...
(Date:2/12/2015)... 12, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce ... 62/113114 for DISTRIBUTED METHOD AND SYSTEM TO ... patent further establishes NXT-ID,s position in the emerging "Internet ... the ability for multiple devices to collaborate with one ...
Breaking Biology News(10 mins):Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 2Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 3ACT Genomics Raises $8 Million in its First Private Funding Round 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3
... The Antarctic ozone hole, which yawns wide every Southern ... It stretched to 10.05 million square miles, the ninth ... the ozone hole reached its deepest point of the ... 10th lowest in this 26-year record. NASA and ...
... data sets for a group of birds and employing ... the evolutionary family tree for one of the most ... the Hawaiian honeycreepers. Not only have the ... family originally evolved from, but they have also linked ...
... 20, 2011) -- Junrong Zheng,s techniques to see the fine ... University scientist a highly prestigious Packard Fellowship. Zheng ... use the five-year grant that comes with the fellowship to ... -- the shape and orientation -- of any molecule, no ...
Cached Biology News:NASA, NOAA data show significant Antarctic ozone hole remains 2NASA, NOAA data show significant Antarctic ozone hole remains 3Scientists determine family tree for most-endangered bird family in the world 2Scientists determine family tree for most-endangered bird family in the world 3Rice's Zheng wins Packard Fellowship 2
... SearchLight® IR Mouse Cytokine Array is a ... the quantitative measurement of 12 cytokines in ... culture supernatants. Each well of the microplate ... specific cytokines in standards and samples added ...
... DNA transformation can be difficult to achieve ... presence of one or more restriction and ... that is recognized as "foreign". TypeOne™ Restriction ... transformation efficiencies in bacterial strains with type ...
... AMPure is a magnetic bead-based ... no sample transfer, centrifugation or ... small and large PCR extension ... microplates. Agencourt AMPure can easily ...
... This kit is designed for the ... large vector plasmids at any position (for ... included loxP-PGK-gb2-neo-loxP cassette is designed to allow ... eukaryotic cells. It combines a prokaryotic promoter ...
Biology Products: